Blockbuster Diabetes Drugs Pioneer New Medical Frontiers

Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond diabetes treatment. These medications, collectively earning billions, are being tested for new medical applications, including alcohol addiction, Alzheimer's, cardiovascular, chronic kidney, liver, neurological disorders, and sleep apnea management.

In a rapidly evolving pharmaceutical landscape, diabetes medications from giants Eli Lilly and Novo Nordisk are pushing boundaries beyond conventional treatment domains. The medications, including Mounjaro, Zepbound, Ozempic, and Wegovy, amassed over $40 billion in sales last year, with a forecast of $60 billion by 2025.

However, the companies face challenges with a rise in generic versions and competition. To counteract these pressures, they are investigating their GLP-1 drugs for various conditions such as alcohol addiction, Alzheimer's, cardiovascular and chronic kidney diseases, liver disorders, and sleep apnea among others.

Significant trials are underway: Novo is studying semaglutide for Alzheimer's, while Lilly explores tirzepatide for heart failure. Sleep apnea treatments saw a breakthrough with Zepbound's recent FDA approval. These efforts aim to diversify usage and insurer coverage, potentially transforming treatment paradigms.

(With inputs from agencies.)